Such compounds could be designed to selectively stabilize specific conformations of SESN2, thereby fine-tuning its functional outputs to achieve a desired therapeutic effect—for example, maximizing its antioxidant and anti-inflammatory roles while minimizing mTORC1 activation in the context of neurodegenerative disease. The gene discussed is SESN2; the disease is neurodegenerative disease.